Cite
HARVARD Citation
Rittberg, R. et al. (n.d.). Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world.. Journal of clinical oncology. 40 (28), p. 126. [Online].